


## Claims

1. The use of a compound of formula (I)



10                                      (wherein R is a C<sub>16-24</sub> unsaturated hydrocarbon group optionally interrupted  $\alpha$ ,  $\beta$ ,  $\gamma$ , or  $\delta$  to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO<sub>2</sub> said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

                                    X is an electron withdrawing group)  
in the manufacture of a medicament for the treatment of psoriasis.

15

2. Use as claimed in claim 1 wherein said hydrocarbon group has 5 to 7 double bonds.

20                                      3. Use as claimed in claim 2 wherein said hydrocarbon group comprises 5 double bonds.

4. Use as claimed in claims 1 to 3 wherein no double bond is conjugated with the carbonyl group.

25                                      5. Use as claimed in any one of claims 1 to 4 wherein all double bonds are in the cis configuration.

30                                      6. Use as claimed in any one of claims 1 to 4 wherein all double bonds are in the cis configuration except the double bond nearest the carbonyl.

7. Use as claimed in any one of claims 1 to 6 wherein the R group comprises 19 to 21 carbon atoms.


35                                      8. Use as claimed in any one of claims 1 to 7 wherein the R group comprises a heteroatom or group of heteroatoms  $\beta$  or  $\gamma$  to the carbonyl.

ART 34 AMDE

16

9. Use as claimed in any one of claims 1 to 8 wherein said heteroatom or group of heteroatoms is O, S or SO.


10. Use as claimed in any one of claims 1 to 9 wherein the RCOX group is:




11. Use as claimed in any one of claims 1 to 10 wherein X is a O-C<sub>1-6</sub> alkyl, CN, CO<sub>2</sub>-C<sub>1-6</sub> alkyl, phenyl, CHal<sub>3</sub>, CHal<sub>2</sub>H, CHalH<sub>2</sub> wherein Hal represents a halogen.

12. Use as claimed in claim 11 wherein X is CHal<sub>3</sub>.

13. Use as claimed in claim 1 wherein RCOX is



or




14. A method of treating psoriasis comprising administering to an animal an effective amount of a compound of formula (I)



(wherein R is a C<sub>16-24</sub> unsaturated hydrocarbon group optionally interrupted  $\alpha$ ,  $\beta$ ,  $\gamma$ , or  $\delta$  to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO<sub>2</sub> said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group).

15. Use of a compound of formula (I)



(wherein R is a C<sub>16-24</sub> unsaturated hydrocarbon group optionally interrupted  $\alpha$ ,  $\beta$ ,  $\gamma$ , or  $\delta$  to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO<sub>2</sub> said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

X is an electron withdrawing group) for use in the manufacture of a medicament for inhibiting the enzyme  
25 IVa PLA<sub>2</sub>.

16. A pharmaceutical composition comprising a compound of formula (I)



(wherein R is a C<sub>16-24</sub> unsaturated hydrocarbon group optionally interrupted  $\alpha$ ,  $\beta$ ,  $\gamma$ , or  $\delta$  to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO<sub>2</sub> said hydrocarbon group comprising at least 5 non-conjugated double bonds; and

X is an electron withdrawing group) and a pharmaceutically acceptable excipient.